Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Simple item page
dc.contributor.authorWatts, Richard A.
dc.contributor.authorMahr, Alfred
dc.contributor.authorMohammad, Aladdin J.
dc.contributor.authorGatenby, Paul
dc.contributor.authorBasu, Neil
dc.contributor.authorFlores-Suárez, Luis Felipe
dc.date.accessioned2015-07-21T05:50:39Z
dc.date.available2015-07-21T05:50:39Z
dc.date.issued2015-04
dc.description.abstractIt is now 25 years since the first European studies on vasculitis--the anti-neutrophil cytoplasmic antibody (ANCA) standardization project. Over that period of time, there have been major developments in the classification of the vasculitides, which has permitted the conduct of high-quality epidemiology studies. Studying the epidemiology of rare diseases such as the ANCA-associated vasculitides (AAV) poses considerable challenges to epidemiologists. The first is the need for a clear definition of a case with good differentiation from similar disorders. The second is case capture. The vasculitides are rare, and therefore, a large population is required to determine the incidence and prevalence, and this poses questions of feasibility. A large population increases the risk of incomplete case detection but permits a reasonable number of cases to be collected in a practicable time frame, whereas a smaller population requires a much longer time frame to collect the necessary cases, which may also not be feasible. Statistical methods of capture-recapture analysis enable estimates to be made of the number of missing cases. The third is case ascertainment. The AAV are virtually always managed in secondary care, and therefore, hospital-based case ascertainment may be appropriate. Fourthly, the rarity of the conditions makes prospective case-control studies investigating risk factors difficult to conduct because the population size required to achieve statistical confidence is in excess of that which is readily available. Thus, much of the data on risk factors are derived from retrospective studies with inherent potential bias.en_AU
dc.format9 pagesen_AU
dc.identifier.urihttp://hdl.handle.net/1885/14362
dc.publisherOxford University Pressen_AU
dc.rights© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.en_AU
dc.sourceNephrology, Dialysis, Transplantationen_AU
dc.subjectancaen_AU
dc.subjectclassificationen_AU
dc.subjectepidemiologyen_AU
dc.subjectvasculitisen_AU
dc.subjecteuropeen_AU
dc.subjecthumansen_AU
dc.subjectincidenceen_AU
dc.subjectanti-neutrophil cytoplasmic antibody-associated vasculitisen_AU
dc.titleClassification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitisen_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.lastpagei22en_AU
local.bibliographicCitation.startpagei14en_AU
local.contributor.affiliationGatenby, P., Medical School, The Australian National Universityen_AU
local.contributor.authoremailpaul.gatenby@anu.edu.auen_AU
local.contributor.authoruidu4044018en_AU
local.identifier.citationvolume30 Suppl 1en_AU
local.identifier.doi10.1093/ndt/gfv022en_AU
local.identifier.essn1460-2385en_AU
local.identifier.uidSubmittedByu1005913en_AU
local.publisher.urlhttp://www.oxfordjournals.org/en/en_AU
local.type.statusPublished Versionen_AU

Downloads

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
884 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2024 LYRASIS